Anti-CD3 x EGFR bispecific antibody redirects cytokine-induced killer cells to glioblastoma in vitro and in vivo

Oncology Reports

Volumn 34, Issue 5, 2015, Pages 2567-2575

  Ma, Pan ^a,b   He, Qiang ^c   Li, Wei ^a   Li, Xianliang ^c   Han, Huamin ^a   Jin, Mengmeng ^d   Zhen Liu, Chang ^a   Tao, Hua ^a   Ma, Juan ^a,e   Gao, Bin ^a,f  

^a INSTITUTE OF MICROBIOLOGY   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d CHINESE PLA GENERAL HOSPITAL   (China)

^e CAPITAL MEDICAL UNIVERSITY   (China)

^f INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

Author keywords

Bispecific antibody; EGFR; Glioblastoma; Immunotherapy; Luciferase

Indexed keywords

BISPECIFIC ANTIBODY; CD3 EPIDERMAL GROWTH FACTOR RECEPTOR BISPECIFIC ANTIBODY; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; GAMMA INTERFERON; GANGLIOSIDE GD2; INTERLEUKIN 2; OKT 3; PROGRAMMED DEATH 1 LIGAND 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CD3 ANTIGEN; EGFR PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; CYTOKINE INDUCED KILLER CELL; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SCID BEIGE MOUSE; SURVIVAL RATE; TUMOR XENOGRAFT; ANIMAL; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFECTS; DRUG SCREENING; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; PROCEDURES; TRANSPLANTATION; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIGENS, CD3; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYTOKINE-INDUCED KILLER CELLS; GLIOBLASTOMA; HUMANS; IMMUNOTHERAPY; IN VITRO TECHNIQUES; MICE; RECEPTOR, EPIDERMAL GROWTH FACTOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84941956455     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.4233     Document Type: Article

References (34)

1. Thakkar JP, Dolecek TA, Horbinski C, Ostrom QT, Lightner DD, Barnholtz-Sloan JS and Villano JL: Epidemiologic and molecular prognostic review of glioblastoma. Cancer Epidemiol Biomarkers Prev 23: 1985-1996, 2014.
2. Stewart LA: Chemotherapy in adult high-grade glioma: A systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359: 1011-1018, 2002.
3. Mellman I, Coukos G and Dranoff G: Cancer immunotherapy comes of age. Nature 480: 480-489, 2011.
4. Agrawal NS, Miller R Jr, Lal R, Mahanti H, Dixon-Mah YN, DeCandio ML, Vandergrift WA III, Varma AK, Patel SJ, Banik NL, et al: Current studies of immunotherapy on glioblastoma. J Neurol Neurosurg 1: 21000104, 2014.
5. Bonavia R, Inda MM, Cavenee WK and Furnari FB: Heterogeneity maintenance in glioblastoma: A social network. Cancer Res 71: 4055-4060, 2011.
6. Gyorki D E, S pillane J, S peakman D, S hackleton M and Henderson MA: Current management of advanced melanoma: A transformed landscape. ANZ J Surg 84: 612-617, 2014.
7. Escudier B and Albiges L: Pazopanib for the treatment of advanced renal cell cancer. Expert Opin Orphan Drugs 2: 605-616, 2014.
8. Capietto AH, Keirallah S, Gross E, Dauguet N, Laprévotte E, Jean C, Gertner-Dardenne J, Bezombes C, Quillet-Mary A, Poupot M, et al: Emerging concepts for the treatment of hematological malignancies with therapeutic monoclonal antibodies. Curr Drug Targets 11: 790-800, 2010.
9. Neyns B, Sadones J, Joosens E, Bouttens F, Verbeke L, Baurain JF, D'Hondt L, Strauven T, Chaskis C, In't Veld P, et al: Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma. Ann Oncol 20: 1596-1603, 2009.
10. Hishii M, Nitta T, Ebato M, Okumura K and Sato K: Targeting therapy for glioma by LAK cells coupled with bispecific antibodies. J Clin Neurosci 1: 261-265, 1994.
11. Jacobs SK, Wilson DJ, Melin G, Parham CW, Holcomb B, Kornblith PL and Grimm EA: Interleukin-2 and lymphokine activated killer (LAK) cells in the treatment of malignant glioma: Clinical and experimental studies. Neurol Res 8: 81-87, 1986.
12. Dillman RO, Duma CM, Schiltz PM, DePriest C, Ellis RA, Okamoto K, Beutel LD, De Leon C and Chico S: Intracavitary placement of autologous lymphokine-activated killer (LAK) cells after resection of recurrent glioblastoma. J Immunother 27: 398-404, 2004.
13. Pfosser A, Brandl M, Salih H, Grosse-Hovest L and Jung G: Role of target antigen in bispecific-antibody-mediated killing of human glioblastoma cells: A pre-clinical study. Int J Cancer 80: 612-616, 1999.
14. Yang I, Tihan T, Han SJ, Wrensch MR, Wiencke J, Sughrue ME and Parsa AT: CD8+ T-cell infiltrate in newly diagnosed glioblastoma is associated with long-term survival. J Clin Neurosci 17: 1381-1385, 2010.
15. Waziri A, Killory B, Ogden AT III, Canoll P, Anderson RC, Kent SC, Anderson DE and Bruce JN: Preferential in situ CD4+CD56+ T cell activation and expansion within human glioblastoma. J Immunol 180: 7673-7680, 2008.
16. Yankelevich M, Kondadasula SV, Thakur A, Buck S, Cheung NK and Lum LG: Anti-CD3 x anti-GD2 bispecific antibody redirects T-cell cytolytic activity to neuroblastoma targets. Pediatr Blood Cancer 59: 1198-1205, 2012.
17. Henriquez NV, van Overveld PG, Que I, Buijs JT, Bachelier R, Kaijzel EL, Löwik CW, Clezardin P and van der Pluijm G: Advances in optical imaging and novel model systems for cancer metastasis research. Clin Exp Metastasis 24: 699-705, 2007.
18. Hontscha C, Borck Y, Zhou H, Messmer D and Schmidt-Wolf IG: Clinical trials on CIK cells: First report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol 137: 305-310, 2011.
19. Han H, Liu Q, He W, Ong K, Liu X and Gao B: An efficient vector system to modify cells genetically. PLoS One 6: e26380, 2011.
20. Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume KG and Weissman IL: Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med 174: 139-149, 1991.
21. Han H, Ma J, Zhang K, Li W, Liu C, Zhang Y, Zhang G, Ma P, Wang L, Zhang G, et al: Bispecific anti-CD3xanti-HER2 antibody mediates T cell cytolytic activity to HER2-positive colorectal cancer in vitro and in vivo. Int J Oncol 45: 2446-2454, 2014.
22. Ma J, Han H, Liu D, Li W, Feng H, Xue X, Wu X, Niu G, Zhang G, Zhao Y, et al: HER2 as a promising target for cytotoxicity T cells in human melanoma therapy. PLoS One 8: e73261, 2013.
23. Fu X, Tao L, Rivera A, Williamson S, Song XT, Ahmed N and Zhang X: A simple and sensitive method for measuring tumorspecific T cell cytotoxicity. PLoS One 5: e11867, 2010.
24. Padfield E, Ellis HP and Kurian KM: Current therapeutic advances targeting EGFR and EGFRvIII in glioblastoma. Front Oncol 5: 5, 2015.
25. Reusch U, Sundaram M, Davol PA, Olson SD, Davis JB, Demel K, Nissim J, Rathore R, Liu PY and Lum LG: Anti-CD3 x anti-epidermal growth factor receptor (EGFR) bispecific antibody redirects T-cell cytolytic activity to EGFR-positive cancers in vitro and in an animal model. Clin Cancer Res 12: 183-190, 2006.
26. Jäkel CE, Vogt A, Gonzalez-Carmona MA and Schmidt-Wolf IG: Clinical studies applying cytokine-induced killer cells for the treatment of gastrointestinal tumors. J Immunol Res 2014: 897214, 2014.
27. Badr CE and Tannous BA: Bioluminescence imaging: Progress and applications. Trends Biotechnol 29: 624-633, 2011.
28. Nogawa M, Yuasa T, Kimura S, Kuroda J, Sato K, Segawa H, Yokota A and Maekawa T: Monitoring luciferase-labeled cancer cell growth and metastasis in different in vivo models. Cancer Lett 217: 243-253, 2005.
29. Tiffen JC, Bailey CG, Ng C, Rasko JE and Holst J: Luciferase expression and bioluminescence does not affect tumor cell growth in vitro or in vivo. Mol Cancer 9: 299, 2010.
30. Patel MA, Kim JE, Ruzevick J, Li G and Lim M: The future of glioblastoma therapy: Synergism of standard of care and immunotherapy. Cancers (Basel) 6: 1953-1985, 2014.
31. Keeren K, Friedrich M, Gebuhr I, Philipp S, Sabat R, Sterry W, Brandt C, Meisel C, Grütz G, Volk HD, et al: Expression of tolerance associated gene-1, a mitochondrial protein inhibiting T cell activation, can be used to predict response to immune modulating therapies. J Immunol 183: 4077-4087, 2009.
32. Swaika A, Hammond WA and Joseph RW: Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy. Mol Immunol Mar 4, 2015 (Epub ahead of print). doi: 10.1016/j. molimm.2015.02.009.
33. Suzuki M and Cheung NK: Disialoganglioside GD2 as a therapeutic target for human diseases. Expert Opin Ther Targets 19: 349-362, 2015.
34. Zhou Z, Luther N, Ibrahim GM, Hawkins C, Vibhakar R, Handler MH and Souweidane MM: B7-H3, a potential therapeutic target, is expressed in diffuse intrinsic pontine glioma. J Neurooncol 111: 257-264, 2013.